Non-steroidal mineralocorticoid receptor antagonists in heart failure

Non-steroidal mineralocorticoid receptor antagonists in heart failure

Novel non-steroidal mineralocorticoid receptor antagonists (MRAs) have improved pharmacological properties compared with steroidal MRAs. Among the non-steroidal MRAs, finerenone has been approved for patients with chronic kidney disease who have diabetes mellitus and has demonstrated favourable safe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews cardiology 2023-10, Vol.20 (10), p.645-646
Hauptverfasser: Filippatos, Gerasimos, Farmakis, Dimitrios
Format: Artikel
Sprache:eng
Schlagworte:
692/699/75/230
692/700/565/1436
Cardiac Imaging
Cardiac Surgery
Cardiology
Clinical Outlook
Diabetes
Ejection fraction
Enzymes
Heart failure
Hospitalization
Hyperkalemia
Kidney diseases
Medicine
Medicine & Public Health
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Novel non-steroidal mineralocorticoid receptor antagonists (MRAs) have improved pharmacological properties compared with steroidal MRAs. Among the non-steroidal MRAs, finerenone has been approved for patients with chronic kidney disease who have diabetes mellitus and has demonstrated favourable safety and promising early results in patients with heart failure.
ISSN:1759-5002
1759-5010
1759-5010
DOI:10.1038/s41569-023-00922-x